Research
Hormonal
Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.
Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.
StrongSupportsmedium confidence
Semaglutide reduced HbA1c by 0.46% of total hemoglobin (95% CI, -0.56% to -0.36%).
Why this rating
Based on the randomized clinical trial design.
Source
Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity
Ashok Ainkaran Ganeshalingam et al. · JAMA Psychiatry · 2025
rct · n=154Cited 21×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →